Business Wire

PA-GROVARA

24.3.2021 17:08:09 CET | Business Wire | Press release

Share
Grovara Raises $5.5 Million Seed Round to Transform Global Commerce with First B2B Global Marketplace for U.S. Healthy Brands

Grovara, the largest B2B global marketplace for U.S. natural and organic brands, announced today the closing of a $5.5 million seed round financing to transform global commerce. David Pottruck led the round and was named Executive Chairman, and he was joined by SPINS, Bluestein Ventures, Spiral Sun Ventures, Siddhi Capital, CEAS Investments, and E and A Venture Capital LLC.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005746/en/

The new investment will be used to expand sales and support resources in key regions worldwide and appoint leadership for brands, sales, and business development. Grovara will also invest in additional supply chain team members, roll out marketing initiatives, develop global partnerships, and continue with product enhancements to its first-to-market technology platform.

“We are happy to be joined by new investors and continue with some long-term partners who have helped us get to this point,” says Grovara Co-Founder and now CEO Abu Kamara, who previously served as Grovara’s President. “Grovara is transforming global commerce for U.S. consumer brands with the first B2B global marketplace for U.S. natural and organic brands. When you lower barriers and simplify exporting to a marketplace, you create tremendous opportunities for brands and retailers to grow their business. It's a game-changer.”

The bridge round comes at a time when the natural and organic food and beverage market and B2B ecommerce are surging. The global natural & organic products market is worth $327B with U.S. brands accounting for $110B, while a recent study of global B2B buyers found 87% of them are purchasing from online marketplaces .

“For as challenging as the last year has been, it has greatly accelerated wellness and digital transformation. Our online B2B global marketplace is positioned perfectly to shepherd this growth and put the healthiest, highest-quality products in front of more retailers who previously did not have access,” says Grovara Co-Founder Peter Groverman, who stepped away from his CEO role to fill the newly created Chief Innovation Officer position. “With this funding round, we can accelerate the onboarding of brands and buyers in our ecosystem to discover, connect and grow their international business.”

In 2020, Grovara launched its technology platform and despite the disruption related to the coronavirus pandemic, continued to grow its portfolio. In 2021, the company anticipates onboarding 200 new brands and 350 additional retailers.

Grovara’s platform, built on a decade of exporting experience, brings access, visibility, and transparency to both brands and buyers via pricing, brand and market insights, and a modern B2C user experience for B2B business.

Nine out of 10 U.S. wellness brands do not export their products, primarily due to the complexities and risks of international business. Grovara’s technology platform is built to manage the export lifecycle and provide wellness-focused, insights-driven data that accelerates growth and scale. Grovara connects major U.S. natural and organic brands like GT’s Living Foods , Wholesome Sweeteners , Honey Stinger , True Citrus , and That’s It with key global retailers like Walmart Mexico , Cencosud , Whole Foods U.K. , and Costco Taiwan .

“My career has been focused on transformational technology and how consumers and businesses use it to create better outcomes,” says Pottruck, former CEO of Charles Schwab. “It’s easy to see how Grovara is well-positioned for this moment with the best technology, the most authority, and industry-leading partners.”

Grovara was recently named a finalist for the Philadelphia Alliance for Capital and Technology (PACT) Enterprise Awards , to be held on June 28, in the Technology Startup category.

ABOUT GROVARA : Grovara is the first B2B global marketplace for natural and organic brands. Grovara increases access to wellness products for global consumers with its proprietary technology platform that connects the most promising U.S. healthy consumer brands with vetted global retailers. With only 1 in 10 wellness brands selling overseas, Grovara enables exporting with visibility, transparency and an intuitive user experience, creating a pathway for dynamic growth potential for American manufacturers and added value for worldwide retailers. More information on Grovara’s market-leading processes and partners can be found at www.grovara.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye